Evidence in multiple cancer types supports the cooperation between activating mutations in KRAS and loss of the G1/S checkpoint by inactivation of CDKN2A or TP53 (Aguirre et al,2003; Courtois‐Cox et al,2008; Schuster et al,2014). Here, CDKN2A is linked to cancer.